TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3.Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2.Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET, BY SERVICE
6.1. Overview
6.2. Pharmaceutical Manufacturing Services
6.3. Drug Development Services
6.4. Biologics Manufacturing Services
7. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET, BY END USER
7.1. Overview
7.2. Small & Mid-Size Pharma
7.3. Generic Pharmaceutical Companies
7.4. Big Pharma
7.5. Other End Users
8. COMPETITIVE LANDSCAPE
8.1. Overview
8.2. Competitive Analysis
8.3. Market Share Analysis
8.4. Major Growth Strategy in the United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market,
8.5. Competitive Benchmarking
8.6. Leading Players in Terms of Number of Developments in the United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market,
8.7. Key Developments and Growth Strategies
8.7.1. New Product Launch/Service Deployment
8.7.2. Merger &Acquisitions
8.7.3. Joint Ventures
8.8. Major Players Financial Matrix
8.8.1. Sales & Operating Income, 2022
8.8.2. Major Players R&D Expenditure.2022
9. COMPANY PROFILES
9.1. Thermo Fisher Scientific Inc. (US)
9.1.1. Company Overview
9.1.2. Financial Overview
9.1.3. Products Offered
9.1.4. Key Developments
9.1.5. SWOT Analysis
9.1.6. Key Strategies
9.2. Catalent (US)
9.2.1. Company Overview
9.2.2. Financial Overview
9.2.3. Products Offered
9.2.4. Key Developments
9.2.5. SWOT Analysis
9.2.6. Key Strategies
9.3. Lonza Group (Switzerland)
9.3.1. Company Overview
9.3.2. Financial Overview
9.3.3. Products Offered
9.3.4. Key Developments
9.3.5. SWOT Analysis
9.3.6. Key Strategies
9.4. Recipharm AB (Sweden)
9.4.1. Company Overview
9.4.2. Financial Overview
9.4.3. Products Offered
9.4.4. Key Developments
9.4.5. SWOT Analysis
9.4.6. Key Strategies
9.5. Vetter Pharma International GMBH (Germany)
9.5.1. Company Overview
9.5.2. Financial Overview
9.5.3. Products Offered
9.5.4. Key Developments
9.5.5. SWOT Analysis
9.5.6. Key Strategies
9.6. FAMAR Health Care Services (Greece)
9.6.1. Company Overview
9.6.2. Financial Overview
9.6.3. Products Offered
9.6.4. Key Developments
9.6.5. SWOT Analysis
9.6.6. Key Strategies
9.7. AbbVie (US)
9.7.1. Company Overview
9.7.2. Financial Overview
9.7.3. Products Offered
9.7.4. Key Developments
9.7.5. SWOT Analysis
9.7.6. Key Strategies
9.8. Aenova Group (Germany)
9.8.1. Company Overview
9.8.2. Financial Overview
9.8.3. Products Offered
9.8.4. Key Developments
9.8.5. SWOT Analysis
9.8.6. Key Strategies
9.9. Consort Medical (UK))
9.9.1. Company Overview
9.9.2. Financial Overview
9.9.3. Products Offered
9.9.4. Key Developments
9.9.5. SWOT Analysis
9.9.6. Key Strategies
9.10. Almac Group (UK)
9.10.1. Company Overview
9.10.2. Financial Overview
9.10.3. Products Offered
9.10.4. Key Developments
9.10.5. SWOT Analysis
9.10.6. Key Strategies
9.11. Siegfried Holding AG (Switzerland)
9.11.1. Company Overview
9.11.2. Financial Overview
9.11.3. Products Offered
9.11.4. Key Developments
9.11.5. SWOT Analysis
9.11.6. Key Strategies
9.12. Boehringer Ingelheim International GmbH (Germany)
9.12.1. Company Overview
9.12.2. Financial Overview
9.12.3. Products Offered
9.12.4. Key Developments
9.12.5. SWOT Analysis
9.12.6. Key Strategies
9.13. Evonik Industries AG (Germany)
9.13.1. Company Overview
9.13.2. Financial Overview
9.13.3. Products Offered
9.13.4. Key Developments
9.13.5. SWOT Analysis
9.13.6. Key Strategies
10. APPENDIX
10.1. References
10.2. Related Reports
LIST OF TABLES
TABLE 1 UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET, SYNOPSIS, 2018-2032
TABLE 2 UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET, ESTIMATES & FORECAST, 2018-2032(USD BILLION)
TABLE 3 UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET, BY SERVICE, 2018-2032 (USD BILLION)
TABLE 4 UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET, BY END USER, 2018-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET
FIGURE 3 MARKET DYNAMICS FOR THE UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET
FIGURE 4 UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET, SHARE (%), BY SERVICE, 2022
FIGURE 5 UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET, SHARE (%), BY END USER, 2022
FIGURE 6 UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET: COMPANY SHARE ANALYSIS, 2022 (%)
FIGURE 7 THERMO FISHER SCIENTIFIC INC. (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 8 THERMO FISHER SCIENTIFIC INC. (US): SWOT ANALYSIS
FIGURE 9 CATALENT (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 10 CATALENT (US): SWOT ANALYSIS
FIGURE 11 LONZA GROUP (SWITZERLAND): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 12 LONZA GROUP (SWITZERLAND): SWOT ANALYSIS
FIGURE 13 RECIPHARM AB (SWEDEN): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 14 RECIPHARM AB (SWEDEN): SWOT ANALYSIS
FIGURE 15 VETTER PHARMA INTERNATIONAL GMBH (GERMANY): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 16 VETTER PHARMA INTERNATIONAL GMBH (GERMANY): SWOT ANALYSIS
FIGURE 17 FAMAR HEALTH CARE SERVICES (GREECE): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 18 FAMAR HEALTH CARE SERVICES (GREECE): SWOT ANALYSIS
FIGURE 19 ABBVIE (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 20 ABBVIE (US): SWOT ANALYSIS
FIGURE 21 AENOVA GROUP (GERMANY): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 22 AENOVA GROUP (GERMANY): SWOT ANALYSIS
FIGURE 23 CONSORT MEDICAL (UK): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 24 CONSORT MEDICAL (UK): SWOT ANALYSIS
FIGURE 25 ALMAC GROUP (UK): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 26 ALMAC GROUP (UK): SWOT ANALYSIS
FIGURE 27 SIEGFRIED HOLDING AG (SWITZERLAND): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 28 SIEGFRIED HOLDING AG (SWITZERLAND): SWOT ANALYSIS
FIGURE 29 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (GERMANY): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 30 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (GERMANY): SWOT ANALYSIS
FIGURE 31 EVONIK INDUSTRIES AG (GERMANY): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 EVONIK INDUSTRIES AG (GERMANY): SWOT ANALYSIS
